Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 113 pages

Showing 101 - 113


multiple myeloma

FDA Grants Priority Review to Carfilzomib Supplemental New Drug Application for Relapsed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has accepted Amgen’s supplemental New Drug Application (sNDA) for carfilzomib (Kyprolis) injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the...

multiple myeloma

FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma

The U.S. Food and Drug Administration (FDA) today approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...

multiple myeloma

FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...

multiple myeloma

Supplemental New Drug Application Submitted for Carfilzomib for Relapsed Multiple Myeloma

Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at...

multiple myeloma

ASH 2014: Ibrutinib Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma

According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, ibrutinib (Imbruvica) demonstrated antitumor activity both as a single agent and in combination with dexamethasone in heavily pretreated patients with relapsed or relapsed/refractory...

multiple myeloma

FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma

The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...

multiple myeloma
sarcoma

Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones

A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...

multiple myeloma

Immunotherapy May Be Effective in the Treatment of Multiple Myeloma

A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma. The findings by ...

multiple myeloma

Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival

A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...

multiple myeloma

Researchers Uncover Root Cause of Multiple Myeloma Relapse

Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...

lymphoma
multiple myeloma

Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm

In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...

multiple myeloma

Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma

FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...

multiple myeloma

FDA Approves Pomalidomide for Advanced Multiple Myeloma

The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...

Advertisement

Advertisement



;
Advertisement